Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.63 |
| ▸ | KISS1R | Q969F8 | 12/20 | 0.62 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440807 | 0.97 | NPY1R (0.59) | BACE1KISS1RBACE2OPRD1NPY1R | |
| SCHEMBL18670433 | 0.95 | BACE1 (0.64) | BACE1KISS1RBACE2NPY1RNPY2R | |
| SCHEMBL1525876 | 0.95 | BACE1 (0.64) | BACE1KISS1RBACE2NPY1RNPY2R | |
| SCHEMBL34471860 | 0.92 | BACE1 (0.67) | BACE1KISS1RBACE2NPY1RNPY2R | |
| SCHEMBL29430948 | 0.92 | KISS1R (0.61) | BACE1KISS1RBACE2NPY1RNPY2R | |
| SCHEMBL4208913 | 0.90 | BACE1 (0.59) | BACE1KISS1RBACE2OPRD1NPY1R | |
| SCHEMBL4208920 | 0.90 | BACE1 (0.59) | BACE1KISS1RBACE2OPRD1NPY1R | |
| SCHEMBL32691437 | 0.90 | BACE1 (0.58) | BACE1KISS1RBACE2OPRD1NPY1R | |
| SCHEMBL30680475 | 0.90 | NPY1R (0.58) | BACE1KISS1RBACE2OPRD1NPY1R | |
| SCHEMBL29730544 | 0.90 | NPY4R (0.58) | BACE1KISS1RBACE2NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516089-B2 | Bacteria based protein delivery | T3 PHARMACEUTICALS AG (CH) | 2026-01-06 | — | — | US | disclosed |
| US-12358955-B2 | Virulence attenuated bacteria based protein delivery | UNIVERSITAET BASEL (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20240401065-A1 | Bacteria-Based Protein Delivery | UNIVERSITAET BASEL (CH) | 2024-12-05 | — | — | US | disclosed |
| US-12091670-B2 | Bacteria-based protein delivery | UNIVERSITAET BASEL (CH) | 2024-09-17 | — | — | US | disclosed |
| US-20240165169-A1 | Pharmaceutical Combinations for Treating Cancer | T3 PHARMACEUTICALS AG (CH) | 2024-05-23 | — | — | US | disclosed |
| US-20240165265-A1 | Pharmaceutical Combinations for Treating Cancer | T3 PHARMACEUTICALS AG (CH) | 2024-05-23 | — | — | US | disclosed |
| EP-4314036-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 Pharmaceuticals AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313310-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 Pharmaceuticals AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-20230382956-A1 | BACTERIA BASED PROTEIN DELIVERY | T3 PHARMACEUTICALS AG (CH) | 2023-11-30 | — | — | US | disclosed |
| US-11827908-B2 | Polypeptide having luciferase activity | SHIMADZU CORPORATION (JP) | 2023-11-28 | — | — | US | disclosed |
| US-11702663-B2 | Bacteria-based protein delivery | UNIVERSITÄT BASEL (CH) | 2023-07-18 | — | — | US | disclosed |
| US-20230148256-A1 | EXPRESSION OF MODIFIED PROTEINS IN A PEROXISOME | PROVENANCE BIO, LLC | 2023-05-11 | — | — | US | disclosed |
| US-11518789-B2 | Virulence attenuated bacteria based protein delivery | UNIVERSITAET BASEL (CH) | 2022-12-06 | — | — | US | disclosed |
| WO-2022200493-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 PHARMACEUTICALS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022200492-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 PHARMACEUTICALS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| US-20220259575-A1 | POLYPEPTIDE HAVING LUCIFERASE ACTIVITY | SHIMADZU CORPORATION (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-4004196-A2 | EXPRESSION OF MODIFIED PROTEINS IN A PEROXISOME | Regents of the University of California (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022090211-A1 | BACTERIA BASED PROTEIN DELIVERY | T3 PHARMACEUTICALS AG (CH) | 2022-05-05 | — | — | WO | disclosed |
| CN-114423861-A | Expression of modified proteins in peroxisomes | 起源生物有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3957645-A1 | VIRULENCE ATTENUATED BACTERIA BASED PROTEIN DELIVERY | Universität Basel (CH) | 2022-02-23 | — | — | EP | disclosed |